Karyopharm Therap (KPTI) Misses Q2 EPS by 52c

Karyopharm Therap (NASDAQ: KPTI) reported Q2 EPS of ($1.02), $0.52 worse than the analyst estimate of ($0.50). Revenue for the quarter came in at $21 thousand versus the consensus estimate of $150 thousand.

For earnings history and earnings-related data on Karyopharm Therap (KPTI) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• Accenture tumbles 16% on guidance cut; announces Dragos, runZero, NetRise deals
• Citi sees this stock as primary lithium demand beneficiary, upgrades to Buy